Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 18/20 | 0.52 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.41 |
| ▸ | KDM5A | P29375 | 6/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095225 | 0.76 | NPY5R (0.41) | — | |
| SCHEMBL16095318 | 0.73 | KDM4C (0.52) | KDM4CKDM2BKDM5AKDM5BKDM4A | |
| SCHEMBL16103402 | 0.68 | KDM4C (0.59) | KDM4CKDM2BKDM5AKDM5BKDM4A | |
| SCHEMBL16034096 | 0.68 | KDM4C (1.00) | KDM4CKDM2BKDM5AKDM5BPHF8 | |
| SCHEMBL16075657 | 0.67 | KDM4C (0.81) | KDM4CKDM2BKDM5AKDM5BPHF8 | |
| SCHEMBL16095046 | 0.66 | KDM4C (0.60) | KDM4CKDM2BKDM5AKDM5B | |
| SCHEMBL16095095 | 0.66 | KDM4C (0.49) | KDM4CKDM2BKDM5AKDM5B | |
| SCHEMBL16102670 | 0.65 | KDM4C (0.61) | KDM4CKDM2BKDM5AKDM5B | |
| SCHEMBL16095134 | 0.65 | KDM4C (0.60) | KDM4CKDM2BKDM5APHF8 | |
| SCHEMBL16095141 | 0.64 | KDM4C (0.61) | KDM4CKDM2BKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |